Saratov JOURNAL of Medical and Scientific Research
Home

Clinical significance of cystatin С and TGF-01 in the assessment of renal function in the surgical treatment of renal cell carcinoma

Year: 2020, volume 16 Issue: №3 Pages: 786-792
Heading: Urology Article type: Original article
Authors: Tarasenko A.I., Rossolovsky A.N., Berezinets O.L., Durnov D.A., Chekhonatskaya M.L., Loiko V.S., Bobylev D.A., Maslyakova G.N.
Organization: First Moscow State Medical University n.a. I.M. Sechenov, Saratov State Medical University
Summary:

Objective: to evaluate the possibility of using cystatin С and TGF-p as prognostic markers of renal impairment and unfavorable oncological results of surgical treatment of renal cell carcinoma (RCC). Material and Methods. We examined 60 patients with RCC. Patients were divided into 3 groups: with RCC after nephrectomy (group 1); after laparo-scopic nephrectomy (group 2); after laparoscopic resection of the tumor (group 3). All patients before the operation on the 7th-10th day, after 1-3 years of postoperative follow-up, the concentrations of cystatin С and TGF-p in the blood serum were studied by solid-phase ELISA. Results. The majority of patients in the groups showed a significant decrease in glomerular filtration rate (GFR) compared to the control, and 3 years after nephrectomy, most patients had stage C3A chronic kidney disease (CKD). The Cystatin С content in all groups of patients with RCC had a statistically significant increase compared to the control (2664, 3103, and 2709 ng/ml in groups 1.2 and 3 versus 143 ng/ml, respectively) (p<0.05). Conclusion. In the majority of patients with RCC, postoperative initiation and progression of "surgical" CKD occurs, which persists 3 years after surgical treatment. Cystatin С can be considered as a predictor of high antitumor activity in patients with RCC, and requires monitoring in the long-term postoperative period.

Keywords: biomolecular markers, cystatin C, renal cell carcinoma, renal function

Bibliography:
1. Liu X, Huang X, Zhao P, Zhang P. Survival benefit of nephron-sparing surgery for patients with pT1 b renal cell carcinoma: A population-based study. Oncol Lett 2020; 19 (1): 498-504.
2. Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017; 198 (3): 520-9.
3. Ellis RJ. Chronic kidney disease after nephrectomy: a clinically-significant entity? Transl Androl Urol 2019; 8 (2): S 166-S174.
4. Patel HD, Pierorazio PM, Johnson MH. Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2017; 12 (7): 1057-69.
5. Mir MC, Derweesh I, Porpiglia F. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017; 71 (4): 606-17.
6. Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012; (188): 51-7.
7. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; (59): 543-52.
8. Cozzi DA, Ceccanti S, Cozzi F. Renal function up to the 5th decade of life after nephrectomy in childhood: a literature review. Nephrology 2018; (23): 397-404.
9. Cherdantseva TM, Bobrov IP, Varlamov SV, et al. Prognostic value of matrix metalloproteinase 9 in renal cell carcinoma. Cancer Urology 2018; 14 (3): 17-24.
10. Kolwijck Е, Kos J, Obermajer N, et al. The balance between extracellular cathepsins and cystatin С is of importance for ovarian cancer. Eur J Clin Invest 2010; (40): 591-9.
11. Xu Y, Ding Y, Li X, Wu X. Cystatin С is a disease-associated protein subject to multiple regulation. Immunol Cell Biol 2015; 93 (5): 442-51. 12. Isaka Y Targeting TGF-p Signaling in Kidney Fibrosis. Int JMolSci2018; 19 (9): 2532.
13. Bogusiawska J, Rodzik K, Popiawski P. TGF-pi targets a microRNA network that regulates cellular adhesion and migration in renal cancer. Cancer Lett 2018; (412): 155-69.
14. Ning J, Zhao Y, Ye Y Opposing roles and potential antagonistic mechanism between TGF-p and BMP pathways: Implications for cancer progression. E Bio Medicine 2019; (41): 702-10.
15. Tarasenko Al, Rossolovsky AN, Berezinets OL, et al. Biomarkers of renal damage and immunohistochemical detection of oncogenesis in the surgical treatment of renal cell carcinoma. Saratov Journal of Medical Scientific Research 2018; 14 (3): 420-6.
16. Lane BR, Demirjian S, Derweesh IH, et al. Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate. Eur Urol 2015; (68): 996-1003.
17. Wu J, Suk-Ouichai C, Dong W, et al. Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery. BJU Int 2018; (121): 93-100.
18. Sokol JP, Schiemann WP Cystatin С antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res 2004; 2 (3): 183-95.
19. Jakos T, PislarA, JewettA, Kos J. Cysteine Cathepsins in Tumor-Associated Immune Cells. Front Immunol 2019; (10): 2037.

AttachmentSize
2020_03_786-792.pdf942.21 KB
All articles of the authors: Berezinetz O.L. , Bobylev D.A., Chekhonatskaya M.L., Durnov D.A., Loyko V.S. , Maslyakova G.N., Napsheva A.M., Tarasenko A.I.

No votes yet